The use of monoclonal antibodies for targeting therapeutic agents to tumours is currently a major area of interest in tumour immunology (Baldwin et al., 1981) . In essence, the aim is to produce conjugates of antibody and a toxic agent which would localise selectively at the tumour site, and thereby exert maximum damage to the tumour cells while minimising effects on normal tissues. Most attention has been focused on the use of plant or bacterial toxins such as the A-chain of ricin, abrin, gelonin, or the A-chain of Diphtheria toxin (Blythman et al., 1981; Gilliland, et al., 1980; Krolick et al., 1980; Trowbridge & Domingo, 1981; Thorpe & Ross, 1982) . These molecules alone are relatively non-toxic, but when combined with an antibody in such a way that they become bound to target cells they become internalised, leading to death of the cell. It has been estimated that a single molecule of such toxins entering the cell could result in cell death, so that this approach could be potentially effective against cells having a low antigen density (Eiklid et al., 1980; Yamaizumi et al., 1978) . For this reason, the antibody portion of the conjugate would need to be highly specific for the tumour, and not react against any, normal cells which are necessary for subsequent survival of the host. In practice, many monoclonal antibodies hitherto believed to be specific for certain tumours are now known to react also against some (Pimm et al., 1982b) . Conjugates of the phase-specific anti-mitotic agent vindesine and polyclonal antibodies have been described previously and been shown in vitro to have cytotoxic effects on human tumour cells (Johnson et al., 1982) . In this study we report the selective action against certain tumour target cells of vindesine coupled to a monoclonal antibody raised against an osteogenic sarcoma cell line.
Materials and methods
Target cells Target cells used in these studies are listed in the Received 11 June 1982; accepted 5 September 1982 5 September . et al., 1981 . This monoclonal antibody is an IgG2b which reacts preferentially with tumour cells rather than normal cells, but is not absolutely specific for osteogenic sarcoma cells. Its reactivity with target cells used in the present study is summarized in the Table. Vindesine-monoclonal antibody conjugate Anti-791T/36 antibody was isolated from ascitic fluid by adsorption onto immobilised Protein A-Sepharose (Pharmacia) at pH8 and 40C, and subsequent elution with 0.1 M citrate/phosphate buffer (pH 3.5). The eluate was neutralised, dialysed against water, lyophilised and reconstituted at 20mg ml-' in 0.34 M borate buffer (pH 8.6) for conjugation. Two conjugates were prepared and purified as described previously (Johnson et al., 1982 , Rowland et al., 1981 . The conjugates were characterised spectroscopically as containing (a) 44 ug ml -1 vindesine (VDS) and 1.33mgml-' a791T/36 Ig at a ratio of 6.5 moles VDS/mole Ig, and (b) Microtiter plates (Sterilin M29 ART) using at least 4 wells/sample. The cells were cultured for 24h at 37°C, then 50 pl of MEM +10% CS containing O.1,uCi of "Se-selenomethionine was added to each well. Samples of the labelled methionine were also added to 200 u1 MEM + 10% NCS in wells containing no cells, to control for non-specific adsorption. The cells were incubated for a further 16h. The supernatant was removed and the cells were washed 3x in PBS, with visual monitoring before and after washing to ensure that cells were not lost during the process. The plates were dried down and sprayed with a plastic sealing film (Nobecutane) and individual wells were separated with a band saw for counting in a y spectrometer. antibody by flow cytometry of treated 791T cells (Figure 2) so it was necessary to use a pretreatment assay to detect target cell specificity. VDS was much less toxic when cells were pre-exposed to it for 15min, followed by 24 h culture, than when they were cultured for 24h in the continuous presence of the drug. This reduction of toxicity was at least 1,000-fold. Accordingly, the toxicity of VDS and VDSa791T/36 conjugate were compared on a series of cell lines whose reactivity with a791T/36 was known (Table) , following exposure to the agent for 15min before cultivation (see Materials and Methods). Purified a791T/36 antibody alone was simultaneously tested on cell lines known to bind it. Effects on 4 osteogenic sarcoma cell lines of conjugate, and free drug and antibody at concentrations equivalent to those in the conjugate, are shown in Figure 3 . The antibody alone had no significant effect on any of the 4 lines (791T, 788T, 2 OS and T278) even though it binds to these cells and is cytotoxic in the presence of added rabbit complement (Price et al., submitted for publication). VDS-a791T/36 conjugate was toxic for all 4 cell lines. In the case of 791T, 2 OS, and T278 it was more toxic than VDS alone, and with 788T it was less toxic, but in all cases cytotoxicity was highly significant at doses of 10igml-' VDS or greater (P<0.001 by Student's test). Complete cytotoxicity was not achieved, presumably because not all target cells entered mitosis during the assay. Figure 4 depicts a comparison between the effects of VDS and the drug-antibody conjugate on 4 cell lines (PAl, T24, Mel-57 and RPMI 5966) which do not react with the antibody. The conjugate had no significant effect on the non-crossreactive cells, even at the highest concentrations tested. VDS alone, however, was as toxic for these cells as it was for the osteogenic sarcomas. Tests on non-reactive cells were performed simultaneously with those on antibody-binding osteogenic sarcomas thus excluding any possibility that toxicity of conjugate for the latter cells was due to free VDS. These experiments clearly show that although the free drug was not discriminatory, the conjugate was selectively toxic for cells which react with the antibody.
Discussion
The selective effect of vindesine coupled to a791T/36 monoclonal antibody resides in the fact that the conjugate was able to bind to the target b.
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. (Table) . cell surface by antibody-antigen interaction. Toxicity of the conjugate was perhaps due to entry into cells during the subsequent culture period. However, from previous studies with radiolabelled antibody and target cells (Baldwin et al., 1981) it is evident that saturation of the binding sites was achieved with much lower levels of antibody than those required to produce cyotoxicity by the conjugate. In the present experiments with conjugate, at the LD50 for 791T cells there were the equivalent of 1011 VDS molecules and 1.5 x 1010 antibody molecules per cell. It is possible that entry of the conjugate takes place during the 15min preincubation period, but only at super-saturating levels.
In previous studies using a vindesine-polyclonal anti-CEA conjugate (Johnson et al., 1982; Rowland et al., 1981) , it was found that a lung carcinoma cell line was much less susceptible to free vindesine than to conjugate. The present study shows no such difference; indeed free vindesine was somewhat more active. This contrast between the two studies cannot be readily explained, but may reflect differences in susceptibility of the cell lines used or may relate to the different properties of a monoclonal and a polyclonal antibody as a carrier.
Although it is difficult to predict the success of in vivo anti-tumour therapy on the basis of in vitro results, the above suggests that if VDS-a791T/36 could bind to tumour cells in vivo, then some antitumour response could be expected. It has been shown that radio-iodinated a791T/36 antibody localises specifically to xenografts of 791T, 788T 2 OS and T278 in immune-deprived mice (Pimm et al., 1982a) so tumour localisation and binding of the drug-antibody conjugate would be likely to occur following parenteral injection. Since VDS is cytotoxic for cells in mitosis, where it disrupts formation of the mitotic spindle, it is likely to affect only cells regularly entering mitosis. In the case of xenografts it is possible that most cells fall into this category, but cells which are normally dormant and enter the mitotic subsequent to eradication of a portion of the tumour population could be subjected to a further treatment of the host with drug-antibody conjugate, if necessary.
Although repeated administration of murine monoclonal antibodies to patients might produce an anti-mouse Ig response, recent clinical studies (Sears et al., 1982; Miller et al., 1982) suggest that problems such as anaphylaxis can be avoided. If human monoclonals with suitable specificities become available (Baldwin et al., 1981) some of the immune response problems should be eliminated. However, the drug portion of a conjugate may still act as an immunological hapten.
The main action of vindesine is as a phasespecific anti-mitotic agent. As such, when coupled to antibody, it offers a potential advantage over antibody-plant toxin conjugates which could kill any non-dividing cell binding the conjugate through antigenic cross-reactivity. Moreover, VDS is already in use clinically and its side-effects are considered to be tolerable.
It is not clear to what extent damage to the drug following chemical coupling would affect therapeutic efficacy of the conjugate. Although the drug could be expected to be less effective directly if administered at normal dosage, binding of the conjugate at the tumour site might counteract the loss of activity. In this case better conjugation methods, resulting in greater preservation of drug activity, could greatly enhance anti-tumour therapy. These questions can only be answered by in vivo experiments, and these are now being initiated using VDS-a791T/36 conjugate and xenografts arising from osteogenic sarcoma lines in immune-deprived mice.
